Jotin Marango is a Managing Director, Senior Research Analyst covering biotechnology and therapeutics. Dr. Marango joined Roth from H.C. Wainwright & Co., where he covered hematology, oncology, and pulmonary therapeutics, with a particular focus on epigenetic and molecularly targeted therapies. Dr. Marango began his career in equity research with Collins Stewart/Canaccord Genuity. Previously, Dr. Marango also served as Chief Operating Officer at the Samuel Waxman Cancer Research Foundation, where he oversaw academic collaborations in translational therapeutics, as well as venture philanthropy initiatives in drug development. Dr. Marango studied theoretical chemistry and classical literature at Harvard University, and later received his M.D. and Ph.D. degrees from the Mount Sinai School of Medicine in New York.